VivoSeq
Oncology

Neuroblastoma

195

Pipeline Programs↗

74

Active Trials↗

69

Companies Involved↗

Neuroblastoma is a highly competitive landscape with 195 programs across 69 companies. The most active players are Ascentage Pharma Group Inc., PersonGen BioTherapeutics (Suzhou) Co., Ltd., Cellectar Biosciences, Inc.. 2 therapies are approved with 36 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

82/100

Pipeline Velocity

30/100

Mech. Concentration

7/100

Completion Rate

76/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.

2 programs

Phase 1P

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

1 program

Phase 1C

Cellectar Biosciences, Inc.

1 program

Phase 1Astellas logo

Astellas

1 program

Phase 1Takeda logo

Takeda

1 program

Phase 1I

Immunex

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical13

Lorlatinib

Pfizer

Dinutuximab

United Therapeutics

Ropivacaine

Fresenius Kabi Oncology Ltd.

Trametinib

Novartis

Ketoconazole

Wim Janssens

Phase 172

Tolcapone

Bausch Health Americas, Inc.

Abemaciclib

Eli Lilly

Alcohol

Astellas

Alisertib

Takeda

Etanercept

Immunex

Phase 272

Antineoplaston A10

Burzynski Research Institute

Sintilimab

Innovent Biologics (Suzhou) Co. Ltd.

Fenretinide

Eastern Cooperative Oncology Group

Tretinoin

Valeant Pharmaceuticals

Eflornithine

USWM, LLC (dba US WorldMeds)

Phase 336

Aldesleukin

Iovance Biotherapeutics, Inc.

Topotecan Hydrochloride

Gynecologic Oncology Group

Etoposide Phosphate

German Society for Pediatric Oncology and Hematology GPOH gGmbH

Sargramostim

Sanofi

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved2

Entrectinib

Roche

Gefitinib

AstraZeneca

Analysis

Modality Breakdown

72%

Small molecule

147 of 204 classified programs — the dominant modality here.

28%ALL OTHERSCell therapy2010%Monoclonal antibody178%Vaccine94%Protein / enzyme84%Radiopharmaceutical2<1%RNA therapy1<1%

Small molecule leads; the ring shows all 204 classified programs, each share of the total. Modality classified for 100% of 238 pipeline programs.

Analysis

Trial Status

260

clinical trials

Completed113 · 43%
Recruiting45 · 17%
Unknown status29 · 11%
Terminated27 · 10%
Active, not recruiting25 · 10%
Withdrawn8 · 3%
Other13 · 5%

Clinical Trials

Trial Activity

260 trials

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06057948·94 enrolled
Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
Recruiting·NNanjing Children's Hospital·Phase 1·NCT06751134·12 enrolled
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT02605421·12 enrolled
18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
Recruiting·FFirst Affiliated Hospital of Zhejiang University·N/A·NCT06852807·200 enrolled
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00107289·200 enrolled
68Ga-DOTATATE Neuroblastoma Imaging Pilot
Recruiting·—·Phase 2·NCT04559217·20 enrolled
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT03721068·18 enrolled
Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma
Recruiting·PPrincess Maxima Center for Pediatric Oncology·Phase 1·NCT06485947·38 enrolled
Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
Recruiting·—·N/A·NCT06818916·30 enrolled
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT06995872·34 enrolled
Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.
Recruiting·SSun Yat-sen University·Phase 1·NCT06631391·30 enrolled
Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors
Recruiting·KKyushu University·Phase 1·NCT05608148·61 enrolled
APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
Recruiting·Ascentage Pharma Group Inc. logoAscentage Pharma Group Inc.·Phase 1·NCT05701306·100 enrolled
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Recruiting·—·Phase 2·NCT06540963·98 enrolled
Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma
Recruiting·UUniversity College, London·Phase 1·NCT05990751·12 enrolled
Page 1 of 18

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)